ArticleCancers2024
De-Escalation of Axillary Surgery in Clinically Node-Positive Breast Cancer Patients Treated with Neoadjuvant Therapy: Comparative Long-Term Outcomes of Sentinel Lymph Node Biopsy versus Axillary Lymph Node Dissection.
Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Article
- Research on Omitting Sentinel Lymph Node Biopsy after Neoadjuvant Therapy in cN1 Breast Cancer Patients.Cancer medicine · 2026Article
- Article
- Review
- Spectral Precision: The Added Value of Dual-Energy CT for Axillary Lymph Node Characterization in Breast Cancer.Cancers · 2026Article
- Axillary Recurrence After a Negative Sentinel Lymph Node Biopsy (SLNB) for Initial Positive Node Breast Cancer Postneoadjuvant Therapy: Insights From a Systematic Review and Meta-Analysis.The breast journal · 2026Review
- Research trends of neoadjuvant therapy for breast cancer: A bibliometric analysis.Human vaccines & immunotherapeutics · 2025Review
- AXINEO: AXIllary response to NEOadjuvant chemotherapy for breast cancer: can we predict response based on a biomarker panel?Archives of gynecology and obstetrics · 2025Article
- Article
- Robot assisted sentinel lymph node biopsy using indocyanine green combined with carbon nanoparticles staining improved detection rates in breast cancer.Scientific reports · 2025Article
- Article
- Predictors of High-Burden Residual Axillary Disease After Neoadjuvant Therapy in Breast Cancer.Cancers · 2025Article
- Retrospective Case-Cohort Study on Risk Factors for Developing Distant Metastases in Women With Breast Cancer.Cancer medicine · 2025Article
- Critical dialogue: recent advancements toward omission of axillary lymph node dissection in clinically node positive breast cancer patients treated with neoadjuvant chemo-immuno therapy: impact on radiology practice.Insights into imaging · 2025Article
- Article
- Omission of Axillary Surgery After Neoadjuvant Therapy in Her2-Positive Breast Cancer: Who Are the Candidates?Cancers · 2025Article
- Impact of Physical Exercise on Breast Cancer-Related Lymphedema and Non-Invasive Measurement Tools: A Systematic Review.Cancers · 2025Review
- Article
- Article
- De-escalation of axillary interventions in the management of breast cancer patients following neoadjuvant systemic treatment.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundsThis study compares the long-term outcomes of axillary lymph node dissection (ALND) versus sentinel lymph node biopsy (SLNB) in clinically node-positive (cN+) breast cancer (BC) patients treated with neoadjuvant therapy (NAT).
methodsWe conducted a retrospective analysis of 322 cN+ BC patients who became clinically node-negative (ycN0) post-NAT. Patients were categorized based on the final type of axillary surgery performed: ALND or SLNB. Recurrence-free survival (RFS), distant disease-free survival (DDFS), overall survival (OS), and breast cancer-specific survival (BCSS) were evaluated and compared between the two groups.
resultsPatients in the SLNB group had significantly better 3-, 5-, and 10-year RFS, DDFS, OS, and BCSS compared to those in the ALND group. The SLNB group also had a higher proportion of patients achieving pathologic complete response (pCR). Multivariate analysis identified pCR, ypN0 status, and SLNB as favorable prognostic factors for all survival metrics. Axillary recurrence rates were low for both groups (0.6-2.1%).
conclusionsSLNB may be a safe and effective alternative to ALND for selected cN+ BC patients who convert to ycN0 after NAT. These findings suggest that careful patient selection is crucial, and further research is needed to validate these results in more comparable populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.